Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. and Anderson, K.C. (2003) A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 348, 2609-2617.
http://dx.doi.org/10.1056/NEJMoa030288

has been cited by the following article:

• TITLE: Bortezomib-Induced Multiple Chalazia: A Case Report

  AUTHORS: Rania Mohamed, Horace Massa, Claude Schwarz, Nicole Grandjean-Hallez, Kaveh Samii

  KEYWORDS: Bortezomib, Chalazion, Meibomian Gland

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.4 No.1, January 19, 2015

  ABSTRACT: Bortezomib is a novel agent for the treatment of patients with multiple myeloma. Several cutaneous lesions have been associated with its use and chalazia have been reported in a few cases with a delayed appearance ranging from 1 to 6 months. We describe the case of a 59-year-old man with multiple myeloma IgG kappa, ISS2, who developed a chalazion induced by bortezomib. Following the failure of conservative treatment, a biopsy was performed to exclude extramedullary plasmocytoma. Bortezomib was discontinued due to the persistence of lesions and a therapeutic approach combining systemic antibiotics with incision and curettage was adopted. An active inflammatory lesion developed after 1 month, similar to that observed under bortezomib therapy. Symptoms resolved only 5 months later and the patient remained free of any ocular manifestation. Physicians should be aware that chalazia may be resistant to conventional treatment and lead to local complications, such as cellulitis.